Quiver Bioscience Inc. has received a multi-year grant from the National Institutes of Health (NIH) to advance its lead Nav1.7-targeted antisense oligonucleotide (ASO), QV-2421, through IND-enabling studies and first-in-human trials for chronic neuropathic pain.

Sichuan University has prepared and tested new diterpenoid alkaloid glycoside derivatives potentially useful for the treatment of pain.

Work at Shanghai 3D Medicines Laboratory Co. Ltd. has led to the discovery of new sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers designed for use in the treatment of pain.

Work at Alicorn Pharmaceutical Co. Ltd. has led to the synthesis of new sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers. They are reported to be useful for the treatment of pain, respiratory and neurological disorders.

Sea4us - Biotecnologia e Recursos Marinhos Lda. has reported oxazolidone-derived compounds potentially useful for the treatment of chronic pain.

Opioids are widely used to relieve the pain associated with oral squamous cell carcinoma (OSCC), but tolerance and undesired effects often limit their use. EGFR is commonly amplified in oral cancer and its involvement in OSCC-associated pain and opioid tolerance was investigated through the sensitization of trigeminal ganglion cells, which are the main sensory neurons that innervate the face and mouth. For this purpose, they used the EGFR inhibitor AG-1478, which was tested in vitro as well as in in vivo in human OSCC and an orthotopic murine models.

Humanwell Pharmaceutical US Inc. has disclosed prodrugs of somatostatin SST4 receptor agonists described as potentially useful for the treatment of visceral and neuropathic pain.